Zhitong Finance App News, Xianjian Technology (01302) announced that on October 19, 2026, the company received an official written notice from the State Drug Administration confirming that the ICS Elpis™ absorbable peripheral expansion film stent system independently developed by Yuanxin Technology (Shenzhen) Co., Ltd., a subsidiary of the company, has entered the China Drug Administration's special review procedure for innovative medical devices. This product is suitable for the treatment of common iliac artery and external iliac atherosclerotic stenosis or occlusive lesions. It is the company's 20th product to enter this procedure by the State Drug Administration.

ICS Elpis ^TM has completed all clinical enrollment in the first human trial (FIM). Research results showed that the success rate of the device and surgery reached 100%, and that blood vessels remained unobstructed after surgery and during follow-up, which initially verified the safety and efficacy of the product.

The Group owns independent intellectual property rights for this product. Currently, the product has obtained clinical trial approval from the State Drug Administration, and a randomized controlled clinical trial study will soon be carried out. As subsequent clinical trials progress steadily, there will be more high-quality evidence-based medical evidence to further confirm the safety and efficacy of this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.